Atlas Trials

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Clinical trial NCT05641831 · RECRUITING

Trial details

NCT number
NCT05641831
Sponsor
Uma Borate
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Clonal Cytopenia of Undetermined Significance
Start date
2023-02-06
Primary completion
2028-12-31
Enrollment
110

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.